



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

产品名称: T-5224

产品别名: T-5224

生物活性:

Description	T-5224 is a transcription factor c-Fos/activator protein (AP)-1 inhibitor with anti-inflammatory effects, which specifically inhibits the DNA binding activity of c-Fos/c-Jun without affecting other transcription factors. T-5224 inhibits the IL-1 β -induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription[1][2].																																						
IC₅₀ & Target	c-Fos/activator protein (AP)-1[1]																																						
In Vitro	T-5224 inhibits in-vitro production of the mediators MMP-1, MMP-3, IL-6 and TNF- α by IL-1 β -stimulated human synovial SW982 cells with the mean IC ₅₀ of about 10 μ M[2]. T-5224 (0-80 μ M) significantly inhibits the invasion, migration, and MMP activity of HSC-3-M3 cells in a dose-dependent manner[3].																																						
In Vivo	Administration of T-5224 (300 mg/kg, p.o.) after intraperitoneal injection of LPS imparts appreciable protection against acute elevations in serum levels of TNF α , HMGB1, ALT/AST as well as in liver tissue levels of MIP-1 α and MCP-1, and reduces the lethality (27%)[4]. G2 is observed in rat and monkey liver microsomes as a major metabolite of T-5224, suggesting that G2 is not a human-specific metabolite[5]. T-5224 (300 mg/kg, p.o.) inhibits the production of TNF-alpha and other downstream effectors in C57BL/6 mice[6].																																						
In Vitro: DMSO : \geq 31 mg/mL (59.90 mM) H ₂ O : < 0.1 mg/mL (insoluble) * " \geq " means soluble, but saturation unknown.	<table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent</th><th>Mass</th><th rowspan="2">Concentration</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr><tr><th></th><th></th><th></th><th></th><th></th><th></th></tr></thead><tbody><tr><td></td><td>1 mM</td><td>1.9323 mL</td><td></td><td>9.6613 mL</td><td></td><td>19.3225 mL</td></tr><tr><td></td><td>5 mM</td><td>0.3865 mL</td><td></td><td>1.9323 mL</td><td></td><td>3.8645 mL</td></tr><tr><td></td><td>10 mM</td><td>0.1932 mL</td><td></td><td>0.9661 mL</td><td></td><td>1.9323 mL</td></tr></tbody></table>					Preparing Stock Solutions	Solvent	Mass	Concentration	1 mg	5 mg	10 mg								1 mM	1.9323 mL		9.6613 mL		19.3225 mL		5 mM	0.3865 mL		1.9323 mL		3.8645 mL		10 mM	0.1932 mL		0.9661 mL		1.9323 mL
Preparing Stock Solutions	Solvent	Mass	Concentration	1 mg	5 mg		10 mg																																
	1 mM	1.9323 mL		9.6613 mL		19.3225 mL																																	
	5 mM	0.3865 mL		1.9323 mL		3.8645 mL																																	
	10 mM	0.1932 mL		0.9661 mL		1.9323 mL																																	
Solvent&Solubility	<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</p> <p>In Vivo:</p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂:</p> <p>——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: \geq 2.08 mg/mL (4.02 mM); Clear solution</p> <p>此方案可获得 \geq 2.08 mg/mL (4.02 mM, 饱和度未知) 的澄清溶液。</p>																																						



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

	<p>以 1 mL 工作液为例, 取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2.请依序添加每种溶剂: 10% DMSO → 90% (20% SBE-β-CD in saline)</p> <p>Solubility: 2.08 mg/mL (4.02 mM); Suspended solution; Need ultrasonic</p> <p>此方案可获得 2.08 mg/mL (4.02 mM)的均匀悬浊液, 悬浊液可用于口服和腹腔注射。</p> <p>以 1 mL 工作液为例, 取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中, 混合均匀。</p> <p>3.请依序添加每种溶剂: 10% DMSO → 90% corn oil</p> <p>Solubility: ≥ 2.08 mg/mL (4.02 mM); Clear solution</p> <p>此方案可获得 ≥ 2.08 mg/mL (4.02 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中, 混合均匀。</p>
References	<p>[1]. Makino H, et al. A selective inhibition of c-Fos/activator protein-1 as a potential therapeutic target for intervertebral disc degeneration and associated pain. <i>Sci Rep.</i> 2017 Dec 5;7(1):16983.</p> <p>[2]. Aikawa Y, et al. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. <i>Nat Biotechnol.</i> 2008 Jul;26(7):817-23.</p> <p>[3]. Kamide D, et al. Selective activator protein-1 inhibitor T-5224 prevents lymph node metastasis in an oral cancer model. <i>Cancer Sci.</i> 2016 May;107(5):666-73.</p> <p>[4]. Izuta S, et al. T-5224, a selective inhibitor of c-Fos/activator protein-1, attenuates lipopolysaccharide-induced liver injury in mice. <i>Biotechnol Lett.</i> 2012 Dec;34(12):2175-82.</p> <p>[5]. Uchihashi S, et al. Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms. <i>Drug Metab Dispos.</i> 2011 May;39(5):803-13.</p> <p>[6]. Miyazaki H, et al. The effects of a selective inhibitor of c-Fos/activator protein-1 on endotoxin-induced acute kidney injury in mice. <i>BMC Nephrol.</i> 2012 Nov 23;13:153.</p>
实验参考:	
Cell Assay	HSC-3-M3 cells are starved for 24 h with DMEM containing 0.5% FBS. The top chamber of the cell invasion device is coated with 50 μ L of 0.1 × basement membrane extract solution and incubated overnight. HSC-3-M3 cells (5.0 × 10 ⁴ cells/well) are added to the top chamber with DMEM containing 0.5% FBS mixed with 0-80 μ M T-5224; DMEM with 10% FBS is added to the bottom chamber and incubated for 48 h. The bottom plate is read using a multilabel plate reader. The data are compared with the standard curve to determine the fraction of invaded cells. [4]
Animal Administration	Mice in LPS group are administered orally with polyvinylpyrrolidone solution in the same volume of T-5224 solution immediately after LPS injection, while in the T-5224 group, mice are administered orally with T-5224 (300 mg/kg, p.o.) in the same manner. In the control group, mice receive polyvinylpyrrolidone solution orally soon after intraperitoneal saline injection. Blood samples are collected for each measurement at the optimal time. [2]
	[1]. Makino H, et al. A selective inhibition of c-Fos/activator protein-1 as a potential therapeutic



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

References	<p>target for intervertebral disc degeneration and associated pain. <i>Sci Rep.</i> 2017 Dec 5;7(1):16983.</p> <p>[2]. Aikawa Y, et al. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. <i>Nat Biotechnol.</i> 2008 Jul;26(7):817-23.</p> <p>[3]. Kamide D, et al. Selective activator protein-1 inhibitor T-5224 prevents lymph node metastasis in an oral cancer model. <i>Cancer Sci.</i>?2016 May;107(5):666-73.</p> <p>[4]. Izuta S, et al. T-5224, a selective inhibitor of c-Fos/activator protein-1, attenuates lipopolysaccharide-induced liver injury in mice. <i>Biotechnol Lett.</i> 2012 Dec;34(12):2175-82.</p> <p>[5]. Uchihashi S, et al. Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms. <i>Drug Metab Dispos.</i> 2011 May;39(5):803-13.</p> <p>[6]. Miyazaki H, et al. The effects of a selective inhibitor of c-Fos/activator protein-1 on endotoxin-induced acute kidney injury in mice. <i>BMC Nephrol.</i> 2012 Nov 23;13:153.</p>
-------------------	--



源叶生物